Rule 64B3-3

Posted in Latest News on January 29, 2019.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque nulla lacus, mattis nec posuere non, porta id enim. Maecenas non volutpat metus. In fermentum enim nunc, nec eleifend metus egestas ut. Quisque vulputate leo tristique, pulvinar orci in, bibendum dolor. Pellentesque eros augue, suscipit in sapien non, dapibus tincidunt libero. Sed a tortor a diam consequat sagittis. Nullam vitae eros sed purus hendrerit vehicula. Nam ac justo vitae arcu interdum lobortis et in est. Nam id arcu tortor. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Nulla tempus justo vitae ex aliquam, vel congue ex iaculis. Vivamus ullamcorper vitae ligula sit amet fringilla.

Phasellus eleifend gravida tellus, at maximus sapien bibendum quis. Duis nec sapien id quam pulvinar placerat ut ut orci. Curabitur lacus est, imperdiet nec diam nec, mattis lobortis nisl. Curabitur a orci sit amet orci sagittis pellentesque. Pellentesque sed mauris sed eros eleifend auctor hendrerit volutpat dolor. Nullam et metus vitae sem posuere fringilla. Duis nec quam id ipsum viverra finibus iaculis et odio. Aenean hendrerit nec tellus maximus sollicitudin. Phasellus eu elit dolor. In consectetur pharetra purus, non fringilla dui aliquet vel. Aliquam vulputate ultrices odio, quis pretium dolor laoreet a. Nunc suscipit non nisl eu cursus. Vestibulum eget leo sit amet tellus facilisis pellentesque.



More Latest News

Important notice regarding Rhopressa
February 12, 2019

The board approved Rhopressa (netarsudil ophthalmic solution) 0.02% for addition to Rule 64B13-18.002. Effective January 25, 2019, Licensees are now permitted to prescribe Rhopressa. Continue reading


Florida Jurisprudence CE Requirement
February 11, 2019

The Board of Optometry voted to waive the 2-hour Florida Jurisprudence requirement for all out-of-state licensees for the current biennium only. Click Here for more information. Continue reading